Bayer: China approves use of finerenone drug
(CercleFinance.com) - Bayer announces that the Chinese National Medical Products Administration (NMPA) has agreed a marketing authorisation for finerenone, with the brand name Kerendia, for the treatment of chronic kidney disease associated with type-2 diabetes (T2D) in adults.
The approval is based on the results of the pivotal Phase III study presented at the American Society of Nephrology (ASN) Kidney Week 2020 and simultaneously published in the New England Journal of Medicine in October 2020.
Copyright (c) 2022 CercleFinance.com. All rights reserved.